The frequency of the p.N264K variant in the Million Veteran Program, an observational cohort study in the Department of Veterans Affairs health care system, is estimated to be 6% in the G1/G2 and G2/G2 high-risk genotypes, but only 0.4% in the whole cohort2; and a precise estimate of the expected prevalence of the variant in a highly specific population of patients with kidney disease and candidate for APOL1 screening is important to consider when introducing an additional genetic target into clinical routine, particularly in terms of cost effectiveness. The gene discussed is APOL1; the disease is kidney disorder.